To evaluate the acute metabolic effects of TRPTI™ in healthy adults under controlled feeding conditions.
Approach:
Study Design: A fixed-sequence, single-blind, placebo-controlled, three-period crossover study involving 37 adults with a BMI of 25–34.9 kg/m².
Intervention: Participants received a single dose of placebo, 150 mg TRPTI™, or 300 mg TRPTI™ following an overnight fast.
Measurements: Blood samples were collected over 8 hours, with standardized meals provided at 15 minutes and 4 hours post dose.
Key Findings:
The 300 mg TRPTI™ dose produced the greatest incretin responses, significantly greater than placebo during selected pre-specified post-dosing and post-prandial periods.
GLP-1 concentrations were approximately 20–25% higher than placebo at key timepoints.
Significant increases in GIP were also observed.
Significant concentration changes in circulating DPP-4 were observed at later time points.
Both TRPTI™ doses were well-tolerated with safety biomarkers remaining within normal ranges.
A statistically significant reduction in meal consumption was observed in both TRPTI™ groups.
Interpretation:
A single 300 mg dose of TRPTI™ enhances post-meal GLP-1 and GIP responses.
Conclusion:
The role of TRPTI™ in nutritional strategies targeting metabolic health requires further investigation.
